Kualitas Hidup Pasien Kanker yang Menjalani Kemoterapi di Rumah Sakit Yogyakarta
Keywords:
rejimen kemoterapi, kanker, kualitas hidup, EORTC QLQ-C30Abstract
Kanker adalah suatu penyakit yang ditandai dengan pertumbuhan sel yang tidak terkendali. Kemoterapi merupakan salah satu penatalaksanaan pengobatan kanker yang memiliki efek samping dan dapat menurunkan kualitas hidup pasien. Kualitas hidup dapat diukur menggunakan kuesioner EORTC QLQ-C30. Penelitian ini bertujuan mengetahui gambaran kualitas hidup pasien kanker serta menganalisis hubungannya dengan karakteristik demografi pasien dan rejimen kemoterapi. Penelitian ini merupakan penelitian observasional cross sectional dengan subjek semua pasien kanker yang menjalani kemoterapi pada saat periode penelitian September-Oktober 2020 serta memenuhi kriteria inklusi. Data yang diperoleh dianalisis menggunakan uji Mann-Whitney dan Kruskal-Wallis. Hasil penelitian menunjukkan terdapat hubungan signifikan antara karakteristik pasien dan regimen kemoterapi dengan beberapa domain kualitas hidup yaitu pada skala fungsi fisik, fungsi peran, fungsi kognitif, gejala kelelahan, gejala sesak nafas dan gejala insomnia (p<0,05).
References
[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA. Cancer J. Clin., vol. 68, no. 6, pp. 394–424, 2018, doi: 10.3322/caac.21492.
[2] WHO, “Indonesia Source GLOBOCAN 2018,” 2019. https://gco.iarc.fr/today/online-analysis.
[3] Riskesdas 2018, "Laporan Provinsi DI Yogyakarta," 2018: Lembaga Penerbit Badan Litbang Kesehatan
[4] Dinkes DIY, “Profil Kesehatan Provinsi Daerah Istimewa Yogyakarta Tahun 2017,” Dinas Kesehat. DIY, pp. 1–224, 2017, [Online].
[5] NCCN, “NCCN Clinical Practice Guidelines in Oncology,” Natl. Compr. Cancer Netw., 2019.
[6] B. J. Alldredge, B. K., Corelli, R. L., Ernst, M. E., & Guglielmo, “Koda-Kimble & Young’s : Applied Therapeutic, The clinical Use of Drugs (10th Edition),” In Lippincott Williams & Wilkins., 2018.
[7] E. Ballatori and F. Roila, “Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy,” Health Qual. Life Outcomes, vol. 1, pp. 1–11, 2003, doi: 10.1186/1477-7525-1-46.
[8] C. Bender, A. Enk, R. Gutzmer, and J. C. Hassel, “Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?,” Cancer Med., vol. 6, no. 7, pp. 1581–1586, 2017, doi: 10.1002/cam4.887.
[9] N. Scherz et al., “Case management to increase quality of life after cancer treatment: A randomized controlled trial,” BMC Cancer, vol. 17, no. 1, pp. 1–8, 2017, doi: 10.1186/s12885-017-3213-9.
[10] D. A. Perwitasari et al., “Impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer,” Int. J. Gynecol. Cancer, vol. 22, no. 1, pp. 139–145, 2012, doi: 10.1097/IGC.0b013e318234f9ee.
[11] D. A. Juwita, A. Almahdy, and R. Afdila, “Penilaian Kualitas Hidup Terkait Kesehatan Pasien Kanker Payudara di RSUP dr. M. Djamil Padang, Indonesia,” J. Ilmu Kefarmasian Indones., vol. 17, no. 1, p. 114, 2019, doi: 10.35814/jifi.v17i1.682.
[12] N. Toulasik, “Analisis Faktor yng Berhubungan dengan Kualitas Hidup Wanita Penderita Kanker di RSUD Prof. Dr. W. Z. Johannes Kupang,” J. Chem. Inf. Model., vol. 53, no. 9, pp. 1689–1699, 2019, doi: 10.1017/CBO9781107415324.004.
[13] A. Hinz et al., “Quality of life in cancer patients—a comparison of inpatient, outpatient, and rehabilitation settings,” Support. Care Cancer, vol. 26, no. 10, pp. 3533–3541, 2018, doi: 10.1007/s00520-018-4211-4.
[14] W. C. Kleijn et al., “Conceptual equivalence and health-related quality of life: An exploratory study in Japanese and Dutch cancer patients,” Qual. Life Res., vol. 15, no. 6, pp. 1091–1101, 2006, doi: 10.1007/s11136-006-0049-1.
[15] D. A. Perwitasari et al., “Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia,” Jpn. J. Clin. Oncol., vol. 41, no. 4, pp. 519–529, 2011, doi: 10.1093/jjco/hyq243.
[16] A. Bottomley, “The Cancer Patient and Quality of Life,” Oncologist, vol. 7, no. 2, pp. 120–125, 2002, doi: 10.1634/theoncologist.7-2-120.
[17] W. Desen, Kemoterapi Tumor Ganas Buku Ajar Onkologi Klinis (II). Balai Penerbit FKUI., 2013.
[18] P. C. Maringka, W. I. Wiyono, and I. Antasionasti, “Penilaian Kualitas Hidup Pada Pasien Kanker di Ruangan Irina Delima RSUP Prof. Dr. R. D. Kandou Manado,” J. Biomedik, vol. 12, no. 2, pp. 139–143, 2020.
[19] I. Nisfulaili, “Gambaran Kualitas Hidup pada Pasien Kanker di RSUP H. Adam Malik,” Fak. Kedokteran, Univ. Sumatera Utara., vol. 1, no. 2, pp. 6–38, 2017.
[20] I. K. Tunas, S. C. Yowani, P. A. Indrayathi, R. Noviyani, and I. N. G. Budiana, “The Assessment Quality of Life For Patients with Cervical Cancer Using Chemotherapy Paclitaxel-Carboplatin in Sanglah,” Indones. J. Clin. Pharm., vol. 5, no. 1, pp. 35–46, 2016, doi: 10.15416/ijcp.2016.5.1.35.
[21] Kemenkes RI, “Buletin kanker. In Buletin Jendela Data dan Informasi Kesehatan,” vol. 53, no. 9, pp. 1689–1699, 2015.
[22] D. D. Agustini, E. Surahman, and R. Abdulah, “Quality of Life Patients with Breast Cancer Therapy Combination Fluorouracil, Doxorubicin, and Cyclofosfamide,” Indones. J. Clin. Pharm., vol. 4, no. 3, pp. 175–185, 2015, doi: 10.15416/ijcp.2015.4.3.175.
[23] P. N. Butow, M. A. Price, M. L. Bell, P. M. Webb, A. Defazio, and M. Friedlander, “Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs,” Gynecol. Oncol., vol. 132, no. 3, pp. 690–697, 2014, doi: 10.1016/j.ygyno.2014.01.002.
[24] J. B. Sanders, A. Loftin, J. S. Seda, and C. Ehlenbeck, “Psychosocial distress affecting patients with ductal carcinoma in situ compared to patients with early invasive breast cancer,” Clin. J. Oncol. Nurs., vol. 18, no. 6, pp. 684–688, 2014, doi: 10.1188/14.CJON.684-688.
[25] R. H. Putri, “Kualitas Hidup Pasien Kanker Ginekologi yang Menjalani Terapi,” J. Aisyah J. Ilmu Kesehat., vol. 2, no. 1, pp. 69–74, 2017, doi: 10.30604/jika.v2i1.34.
[26] P. Urivi, Menu Untuk Penderita Kanker. Puspa Swara, 2002.
[27] S. Ganesh, M. S. Lye, and F. N. Lau, “Quality of life among breast cancer patients in Malaysia,” Asian Pacific J. Cancer Prev., vol. 17, no. 4, pp. 1677–1684, 2016, doi: 10.7314/APJCP.2016.17.4.1677.
[28] N. W. Chang, K. C. Lin, W. H. Hsu, S. C. Lee, J. Y. H. Chan, and K. Y. Wang, “The effect of gender on health-related quality of life and related factors in post-lobectomy lung-cancer patients,” Eur. J. Oncol. Nurs., vol. 19, no. 3, pp. 292–300, 2015, doi: 10.1016/j.ejon.2014.10.015.
[29] N. Wulandari, H. Bahar, and C. Ismail, “Gambaran Kualitas Hidup Pada Penderita Kanker Payudara Di Rumah Sakit Umum Bahteramas Provinsi Sulawesi Tenggara Tahun 2017,” J. Ilm. Mhs. Kesehat. Masy. Unsyiah, vol. 2, no. 6, p. 183119, 2017.
[30] NCI, “In NCI. National Cancer Instutute, USA.gov.” 2019, [Online]. Available: http://www.cancer.gov.
[31] I. Ahyar, I. T. Rachman, and A. Kusumanto, “Perbandingan Kualitas Hidup Penderita Kanker Ovarium Epitelial yang diberikan kemoterapi regimen Paclitaxel dan Carboplatin dengan regimen Cyclophosphamide, Adriamicyn dan Cisplatin di RSUP DR. Sardjito,” J. Kesehat. Reproduksi, vol. 4, pp. 1–10, 2017.
[32] C. U. R. Avelino, R. M. Cardoso, S. S. de Aguiar, and M. J. S. da Silva, “Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel,” J. Bras. Pneumol., vol. 41, no. 2, pp. 133–142, 2015, doi: 10.1590/s1806-37132015000004367.
[2] WHO, “Indonesia Source GLOBOCAN 2018,” 2019. https://gco.iarc.fr/today/online-analysis.
[3] Riskesdas 2018, "Laporan Provinsi DI Yogyakarta," 2018: Lembaga Penerbit Badan Litbang Kesehatan
[4] Dinkes DIY, “Profil Kesehatan Provinsi Daerah Istimewa Yogyakarta Tahun 2017,” Dinas Kesehat. DIY, pp. 1–224, 2017, [Online].
[5] NCCN, “NCCN Clinical Practice Guidelines in Oncology,” Natl. Compr. Cancer Netw., 2019.
[6] B. J. Alldredge, B. K., Corelli, R. L., Ernst, M. E., & Guglielmo, “Koda-Kimble & Young’s : Applied Therapeutic, The clinical Use of Drugs (10th Edition),” In Lippincott Williams & Wilkins., 2018.
[7] E. Ballatori and F. Roila, “Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy,” Health Qual. Life Outcomes, vol. 1, pp. 1–11, 2003, doi: 10.1186/1477-7525-1-46.
[8] C. Bender, A. Enk, R. Gutzmer, and J. C. Hassel, “Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?,” Cancer Med., vol. 6, no. 7, pp. 1581–1586, 2017, doi: 10.1002/cam4.887.
[9] N. Scherz et al., “Case management to increase quality of life after cancer treatment: A randomized controlled trial,” BMC Cancer, vol. 17, no. 1, pp. 1–8, 2017, doi: 10.1186/s12885-017-3213-9.
[10] D. A. Perwitasari et al., “Impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer,” Int. J. Gynecol. Cancer, vol. 22, no. 1, pp. 139–145, 2012, doi: 10.1097/IGC.0b013e318234f9ee.
[11] D. A. Juwita, A. Almahdy, and R. Afdila, “Penilaian Kualitas Hidup Terkait Kesehatan Pasien Kanker Payudara di RSUP dr. M. Djamil Padang, Indonesia,” J. Ilmu Kefarmasian Indones., vol. 17, no. 1, p. 114, 2019, doi: 10.35814/jifi.v17i1.682.
[12] N. Toulasik, “Analisis Faktor yng Berhubungan dengan Kualitas Hidup Wanita Penderita Kanker di RSUD Prof. Dr. W. Z. Johannes Kupang,” J. Chem. Inf. Model., vol. 53, no. 9, pp. 1689–1699, 2019, doi: 10.1017/CBO9781107415324.004.
[13] A. Hinz et al., “Quality of life in cancer patients—a comparison of inpatient, outpatient, and rehabilitation settings,” Support. Care Cancer, vol. 26, no. 10, pp. 3533–3541, 2018, doi: 10.1007/s00520-018-4211-4.
[14] W. C. Kleijn et al., “Conceptual equivalence and health-related quality of life: An exploratory study in Japanese and Dutch cancer patients,” Qual. Life Res., vol. 15, no. 6, pp. 1091–1101, 2006, doi: 10.1007/s11136-006-0049-1.
[15] D. A. Perwitasari et al., “Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia,” Jpn. J. Clin. Oncol., vol. 41, no. 4, pp. 519–529, 2011, doi: 10.1093/jjco/hyq243.
[16] A. Bottomley, “The Cancer Patient and Quality of Life,” Oncologist, vol. 7, no. 2, pp. 120–125, 2002, doi: 10.1634/theoncologist.7-2-120.
[17] W. Desen, Kemoterapi Tumor Ganas Buku Ajar Onkologi Klinis (II). Balai Penerbit FKUI., 2013.
[18] P. C. Maringka, W. I. Wiyono, and I. Antasionasti, “Penilaian Kualitas Hidup Pada Pasien Kanker di Ruangan Irina Delima RSUP Prof. Dr. R. D. Kandou Manado,” J. Biomedik, vol. 12, no. 2, pp. 139–143, 2020.
[19] I. Nisfulaili, “Gambaran Kualitas Hidup pada Pasien Kanker di RSUP H. Adam Malik,” Fak. Kedokteran, Univ. Sumatera Utara., vol. 1, no. 2, pp. 6–38, 2017.
[20] I. K. Tunas, S. C. Yowani, P. A. Indrayathi, R. Noviyani, and I. N. G. Budiana, “The Assessment Quality of Life For Patients with Cervical Cancer Using Chemotherapy Paclitaxel-Carboplatin in Sanglah,” Indones. J. Clin. Pharm., vol. 5, no. 1, pp. 35–46, 2016, doi: 10.15416/ijcp.2016.5.1.35.
[21] Kemenkes RI, “Buletin kanker. In Buletin Jendela Data dan Informasi Kesehatan,” vol. 53, no. 9, pp. 1689–1699, 2015.
[22] D. D. Agustini, E. Surahman, and R. Abdulah, “Quality of Life Patients with Breast Cancer Therapy Combination Fluorouracil, Doxorubicin, and Cyclofosfamide,” Indones. J. Clin. Pharm., vol. 4, no. 3, pp. 175–185, 2015, doi: 10.15416/ijcp.2015.4.3.175.
[23] P. N. Butow, M. A. Price, M. L. Bell, P. M. Webb, A. Defazio, and M. Friedlander, “Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs,” Gynecol. Oncol., vol. 132, no. 3, pp. 690–697, 2014, doi: 10.1016/j.ygyno.2014.01.002.
[24] J. B. Sanders, A. Loftin, J. S. Seda, and C. Ehlenbeck, “Psychosocial distress affecting patients with ductal carcinoma in situ compared to patients with early invasive breast cancer,” Clin. J. Oncol. Nurs., vol. 18, no. 6, pp. 684–688, 2014, doi: 10.1188/14.CJON.684-688.
[25] R. H. Putri, “Kualitas Hidup Pasien Kanker Ginekologi yang Menjalani Terapi,” J. Aisyah J. Ilmu Kesehat., vol. 2, no. 1, pp. 69–74, 2017, doi: 10.30604/jika.v2i1.34.
[26] P. Urivi, Menu Untuk Penderita Kanker. Puspa Swara, 2002.
[27] S. Ganesh, M. S. Lye, and F. N. Lau, “Quality of life among breast cancer patients in Malaysia,” Asian Pacific J. Cancer Prev., vol. 17, no. 4, pp. 1677–1684, 2016, doi: 10.7314/APJCP.2016.17.4.1677.
[28] N. W. Chang, K. C. Lin, W. H. Hsu, S. C. Lee, J. Y. H. Chan, and K. Y. Wang, “The effect of gender on health-related quality of life and related factors in post-lobectomy lung-cancer patients,” Eur. J. Oncol. Nurs., vol. 19, no. 3, pp. 292–300, 2015, doi: 10.1016/j.ejon.2014.10.015.
[29] N. Wulandari, H. Bahar, and C. Ismail, “Gambaran Kualitas Hidup Pada Penderita Kanker Payudara Di Rumah Sakit Umum Bahteramas Provinsi Sulawesi Tenggara Tahun 2017,” J. Ilm. Mhs. Kesehat. Masy. Unsyiah, vol. 2, no. 6, p. 183119, 2017.
[30] NCI, “In NCI. National Cancer Instutute, USA.gov.” 2019, [Online]. Available: http://www.cancer.gov.
[31] I. Ahyar, I. T. Rachman, and A. Kusumanto, “Perbandingan Kualitas Hidup Penderita Kanker Ovarium Epitelial yang diberikan kemoterapi regimen Paclitaxel dan Carboplatin dengan regimen Cyclophosphamide, Adriamicyn dan Cisplatin di RSUP DR. Sardjito,” J. Kesehat. Reproduksi, vol. 4, pp. 1–10, 2017.
[32] C. U. R. Avelino, R. M. Cardoso, S. S. de Aguiar, and M. J. S. da Silva, “Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel,” J. Bras. Pneumol., vol. 41, no. 2, pp. 133–142, 2015, doi: 10.1590/s1806-37132015000004367.
Downloads
Published
2021-12-08
How to Cite
Yuniarti, E., Supadmi, W., Wahyuni, F. A., & Ratna, R. (2021). Kualitas Hidup Pasien Kanker yang Menjalani Kemoterapi di Rumah Sakit Yogyakarta. Prosiding University Research Colloquium, 594–606. Retrieved from https://repository.urecol.org/index.php/proceeding/article/view/1628
Issue
Section
Articles
License
Copyright (c) 2021 Endang Yuniarti, Woro Supadmi, Fitri Ayu Wahyuni, R Ratna
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
